Objective: To compare the clinical features and prognosis between newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients with and without hemophagocytic syndrome (HPS).
Methods: The clinical data of 45 DLBCL patients in Gansu Provincial Hospital from January 2012 to December 2021 were retrospectively analyzed. The patients were divided into HPS group (15 cases) and non-HPS group (30 cases). The clinical features and prognosis of the two groups were compared, and survival analysis was performed using Kaplan-Meier method.
Results: Patients with HSP were mostly characterized by fever, cytopenia and splenomegaly. The levels of ferritin and soluble CD25 increased in all patients. The level of fibrinogen decreased in 66.67% patients, while triglyceride increased in 53.33% patients, and bone marrow hemophagocytosis occurred in 80.00% patients. Compared with non-HSP group, the proportions of patients with advanced stage (Ann Arbor stage III/IV) and lactate dehydrogenase (LDH) ≥240 U/L were higher in HSP group (both P < 0.05). The median survival time of HSP group was 8.0 months, which was significantly shorter than 45.5 months of non-HSP group (P < 0.001).
Conclusion: The DLBCL patients with HPS have later Ann Arbor stage, higher LDH and shorter overall survival time compared with patients without HPS.
题目: 弥漫大B细胞淋巴瘤初诊时合并噬血细胞综合征的临床特征与预后分析.
目的: 比较弥漫大B细胞淋巴瘤初诊时合并噬血细胞综合征（HPS）与不合并HPS患者的临床特征和预后差异。.
方法: 回顾性分析2012年1月至2021年12月就诊甘肃省人民医院的45例弥漫大B细胞淋巴瘤患者的临床资料，按初诊时是否伴HPS分为合并HPS组（15例）和不合并HPS组（30例），比较两组患者临床特征及预后差异，并应用Kaplan-Meier法进行生存分析。.
结果: 合并HSP组的患者多以发热、血细胞减少、脾大为突出表现；所有患者铁蛋白、可溶性CD25水平升高；66.67%的患者纤维蛋白原水平降低，53.33%的患者甘油三酯水平升高，80.00%的患者出现骨髓噬血现象。与不合并HSP组相比，合并HSP组的进展期（Ann Arbor分期Ⅲ/Ⅳ期）患者和乳酸脱氢酶≥240 U/L患者所占比例较高（均P < 0.05）。合并HSP组中位生存时间为8.0个月，而不合并HSP组的中位生存时间为45.5个月，比较差异有统计学意义（P < 0.001）。.
结论: 弥漫大B细胞淋巴瘤初诊时合并HPS的患者与不合并HPS的患者相比，Ann Arbor分期晚、乳酸脱氢酶水平高，总体生存时间较短。.
Keywords: diffuse large B-cell lymphoma; hemophagocytic syndrome; clinical features; prognosis.